NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: ALEMBICLTD · data 2026-10-31
Alembic Limited
In plain words
Price: 25.9% below its 52-week high of ₹117.72.
Delivery: 52.8% of traded shares were kept for delivery over the last 10 sessions, against 48.2% over the last 60.
Latest results: a net profit of ₹65 cr for the quarter ended Jun 2026 (+5.3% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹239 cr |
| Net profit (last 12 months) | ₹321 cr |
| Sales growth, 3 years (yearly) | 23.6% |
| Profit growth, 3 years (yearly) | 18.5% |
At a glance
Promoters 71.4% (+0.5 pts in a year), pledged 0.0%, institutions 1.4%.
P/E 7.0, dividend yield 2.8%. Price relative to earnings and book value (low is cheaper, not better).
ROE 13.3%, ROCE 3.3%, operating margin 31.3%: how much profit it earns on the money it uses.
Debt/equity 0.00, Profit growth 18.5% and sales growth 23.6% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
- Healthy operating margin (31.3%).
- Profit grew 18.5% a year over 3 years.
- Pays a dividend yielding 2.8%.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
ALEMBICLTD Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹48.74 crore, down 2% YoY and down 18.8% QoQ.
Net profit was ₹64.89 crore, up 5.3% YoY and down 3.3% QoQ.
Operating margin was 31.7% (39.4% a year ago).
EPS was ₹2.53, up 5.4% YoY and down 3.1% QoQ.
ALEMBICLTD के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹48.74 करोड़; पिछले साल की तुलना में 2% की गिरावट, पिछली तिमाही की तुलना में 18.8% की गिरावट।
शुद्ध मुनाफ़ा: ₹64.89 करोड़; पिछले साल की तुलना में 5.3% की बढ़त, पिछली तिमाही की तुलना में 3.3% की गिरावट।
ऑपरेटिंग मार्जिन: 31.7% (एक साल पहले 39.4%)।
EPS: ₹2.53; पिछले साल की तुलना में 5.4% की बढ़त, पिछली तिमाही की तुलना में 3.1% की गिरावट।
ALEMBICLTDના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹48.74 કરોડ; ગયા વર્ષની સરખામણીએ 2% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 18.8% ઘટાડો.
ચોખ્ખો નફો: ₹64.89 કરોડ; ગયા વર્ષની સરખામણીએ 5.3% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 3.3% ઘટાડો.
ઓપરેટિંગ માર્જિન: 31.7% (એક વર્ષ પહેલાં 39.4%).
EPS: ₹2.53; ગયા વર્ષની સરખામણીએ 5.4% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 3.1% ઘટાડો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
15/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 10/30: Delivery 49.2% over the last 20 sessions vs 26.3% in the 40 before (1.87x); shares delivered per day 0.44x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Dividend
- 11 Aug 26Results Q1 FY27 results: profit +5.3% YoY -0.1% next session
- 4 Aug 26Dividend Dividend ₹2.4 (ex-date) -4.9% next session
- 19 May 26Results Q4 FY26 results: profit −1.9% YoY -1.2% next session
- 12 Feb 26Results Q3 FY26 results: profit −8.0% YoY -3.7% next session
- 10 Nov 25Results Q2 FY26 results: profit +6.2% YoY +1.0% next session
- 12 Aug 25Results Q1 FY26 results: profit +10.4% YoY -3.4% next session
- 5 Aug 25Dividend Dividend ₹2.4 (ex-date) -4.7% next session
- 13 May 25Results Q4 FY25 results: profit −5.1% YoY +3.0% next session
- 7 Feb 25Results Q3 FY25 results: profit +6.5% YoY -4.0% next session
- 8 Nov 24Results Q2 FY25 results: profit +33.5% YoY +2.0% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹49 cr | ₹65 cr | +5.3% | 31.7% | 2.53 |
| Mar 2026 | ₹60 cr | ₹67 cr | -1.9% | 33.7% | 2.61 |
| Dec 2025 | ₹74 cr | ₹60 cr | -8.0% | 36.9% | 2.34 |
| Sept 2025 | ₹56 cr | ₹128 cr | +6.2% | 41.6% | 5 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 71.41% | 70.88% | 70.88% | 70.88% |
| Foreign institutions (FII) | 1.34% | 1.25% | 1.25% | 1.28% |
| Domestic institutions (DII) | 0.05% | 0.05% | 0.05% | 0.05% |
| Mutual funds | 0.00% | 0.00% | 0.00% | 0.00% |
| Retail investors | 19.10% | 19.31% | 19.23% | 19.33% |
| Number of shareholders | 1,00,706 | 1,01,238 | 1,02,008 | 1,04,103 |
Common questions
What was Alembic Limited's latest quarterly profit?
Alembic Limited reported a net profit of ₹65 cr for the quarter ended Jun 2026 (+5.3% on the same quarter a year earlier), on revenue of ₹49 cr.
How much do promoters hold in Alembic Limited?
Promoters held 71.41% of Alembic Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Alembic Limited debt-free?
Its latest reported debt-to-equity ratio is 0, so it carries little or no borrowing on the balance sheet.
What is Alembic Limited's P/E ratio?
About 7, based on the last 12 months' earnings and a price of ₹87.22 (data 2026-10-31).
What is the 52-week high and low of Alembic Limited?
The 52-week high is ₹117.72 and the 52-week low is ₹70.46.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Alembic Limited | ₹87.22 | ₹2,239 cr | 7 | — | 13.3% | 3.3% | 0 | -13.2% |
| Sai Parenterals Limited | ₹521.95 | ₹2,302 cr | — | — | 4.9% | 5.8% | 0.96 | +30.5% |
| Dishman Carbogen Amcis Ltd. | ₹145.02 | ₹2,276 cr | 33.3 | — | 1.6% | 2.6% | 0.46 | -50.5% |
| Fredun Pharmaceuticals Ltd. | ₹1,367 | ₹2,259 cr | 49.7 | — | 15.6% | 33% | 0.87 | -11.2% |
| Sakar Healthcare Ltd | ₹944.8 | ₹2,074 cr | 49 | 6.1 | 10% | 12.4% | 0.17 | +167.0% |
| Beta Drugs Ltd. | ₹1,798.4 | ₹2,000 cr | 36.9 | 4.6 | 18.8% | 16.6% | 0.62 | -4.8% |
Compare ALEMBICLTD with SAIPARENT in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open ALEMBICLTD in NSE Scanner →